Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma Inc. was a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases affecting bone health and blood vessel function. Its news centered on the PPi-Adenosine Pathway, the ENPP1 Fc fusion protein enzyme replacement therapy INZ-701, and clinical development for ENPP1 Deficiency, with additional references to related mineralization and vascular conditions.
Company updates also covered ENERGY trial data, disease natural-history publications, operating and financial results, program prioritization, healthcare-conference participation, governance and capital-structure matters, and the completed acquisition of Inozyme by BioMarin Pharmaceutical in July 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.